Should There Be a Standard Therapy for Mantle Cell Lymphoma?

Mitchell R Smith


Future Oncol. 2011;7(2):227-237. 

In This Article

Allogeneic Stem Cell Transplant

Allogeneic SCTs are experimental for MCL. The use of nonmyeloablative approaches to reduce early mortality make this feasible in a higher proportion of patients, although their use generally remains limited to relapsed patients. Graft-versus-MCL effects as an immunotherapy is of potential benefit. Some small studies with interesting results require additional numbers and longer follow-up,[65,66] although there are some long-term disease-free survivors [101]. The use of allo-SCT to consolidate initial remission, in the hope of providing a plateau in survival, would be possible if we were able to reduce short-term mortality and identify a particularly high-risk MCL population that would benefit.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.